Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DBF4 is the regulatory subunit of the Cdc7-Dbf4 kinase (DDK) complex, essential for the initiation of DNA replication during the S phase of the cell cycle. DBF4 protein levels oscillate during the cell cycle, peaking at the G1/S transition and remaining high through S and G2/M phases, thereby controlling Cdc7 kinase activity. The DBF4/Cdc7 complex phosphorylates the minichromosome maintenance (MCM) protein complex, activating it for DNA unwinding and replication fork assembly[1][2][3][4]. DBF4 is considered a promising therapeutic target in cancer due to its role in promoting cell cycle progression and DNA synthesis, and its overexpression is linked to neoplastic transformation in some tumor types[3]. Drugs that inhibit this kinase complex prevent the initiation of DNA replication, leading to cell cycle arrest and potential selective toxicity in rapidly proliferating cells[3][4].
Inhibition of Cdc7-Dbf4 kinase activity, blockade of DNA replication initiation, cell cycle arrest
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DBF4-dependent kinase regulatory subunit (DBF4).